Securities code: 002432 securities abbreviation: Andon Health Co.Ltd(002432) Announcement No.: 2022-022 Andon Health Co.Ltd(002432)
Announcement of abnormal fluctuations in stock trading
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and bear joint and several liabilities for false records, misleading statements or major omissions in the announcement.
1、 Introduction to abnormal fluctuations in stock trading
Andon Health Co.Ltd(002432) (hereinafter referred to as “the company”) shares (stock abbreviation: IX)
Ann medical, stock code: 002432) has accumulated more than 20% of the deviation value of the closing price increase for two consecutive trading days (January 27 and January 28, 2022). According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, it belongs to the abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
The company checked the abnormal fluctuation of the company’s share price, and the results are as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage.
2. The company, controlling shareholders and actual controllers have no major events that should be disclosed but not disclosed or are in the planning stage.
3. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently.
4. Recently, the production and operation of the company is normal, and the internal and external business environment has not changed significantly. Son of the United States
The company signed a change contract with American ACC on the original purchase contract, which included 250 million ihealth people in the original contract
Based on the purchase of kit products, 104166665 people of ihealth kit products will be purchased.
For details of the above matters, please refer to the securities times, China Securities Journal and giant securities published on January 27, 2022
Tide information network（ http://www.cn.info.com.cn. ）Announcement on the progress of major contracts for the daily operation of the company’s U.S. subsidiaries (Announcement No. 2022-021).
5. The controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
6. The company does not violate the provisions on fair information disclosure.
3、 Whether there is a description of the situation that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares and their derivatives that should be disclosed in accordance with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Risk tips
From the technical indicators of the secondary market, as of January 28, Hithink Royalflush Information Network Co.Ltd(300033) showed the company’s dynamic P / E ratio of 441.89; In terms of price to book ratio, as of the closing on January 28, the closing price of the company’s shares in the secondary market was 61.71 yuan / share, Hithink Royalflush Information Network Co.Ltd(300033) showed that the company’s price to book ratio was 14.72. At present, the above data of the company are relatively high compared with the company’s historical stock price and P / E ratio, which does not rule out the risk of falling of the company’s stock price and the above indicators in the future.
Please note that the single month performance of the kit product does not represent the annual performance, and the historical performance of the product does not represent the future performance. The company believes that it is necessary to give another risk prompt, as follows:
1. Risk of uncertainty in the development of the epidemic in the United States: the demand for the company’s antigen home self-test kit products is directly related to the development of the epidemic in the United States. Virus variation, vaccination and the introduction of covid-19 drugs all have an impact on the development of the epidemic. Therefore, the development of the epidemic in the future has strong uncertainty, This uncertainty may greatly affect the demand of kit products;
2. Uncertainty risk of market competition: at present, many companies’ antigen home self-test OTC kit products and covid-19 detection products used in POC use scenarios have been authorized by the U.S. FDA EUA. It cannot be ruled out that more companies will obtain such authorization and enter the market to sell kit products in the future. With the change of market competition situation, The existing market share and product price of a single enterprise may be impacted;
3. Rationality risk of valuation model: the sales of the company’s kit products are highly related to the development of the epidemic, and the trend of the epidemic is difficult to predict, so the long-term impact of the product on the company’s fundamentals is also difficult to predict. Investors are reminded to pay attention to the rationality of the stock price combined with their own valuation model, and there are many factors affecting the stock price of the secondary market. Investors are reminded to pay attention to investment risk, Rational investment;
4. Information reliability risk: the company’s answers on the interactive platform are based on the company’s disclosed information, Amazon America’s information and public information. There is no compilation without objective basis, and the information required to be disclosed in the information disclosure regulations of listed companies and not yet disclosed has not been disclosed in any form, especially involving production, sales Sales and other relevant information. Investors are requested to follow the official information released by the company, do not believe the rumors, and do not presumptuously calculate the sales data and profits of the company’s kit products, resulting in miscalculation and investment loss;
5. Exchange rate fluctuation risk: the company’s kit products are settled in US dollars; With the expansion of sales scale, the amount of foreign currency held by the company will further increase. In view of the uncertainty of exchange rate fluctuations, the company will adjust the product sales price accordingly according to the exchange rate changes, and will consider locking the exchange rate by signing relevant agreements with banks to prevent the risk of large exchange rate fluctuations. However, if the fluctuation range is large in the short term, the company may have exchange losses, which will have an adverse impact on the company’s operating performance;
6. Logistics transportation risk: due to the epidemic in the United States, the current shortage of transportation capacity in air and sea transportation channels continues, port congestion and serious backlog of goods. If the shipped goods cannot be picked up in time, it will have an adverse impact on product sales;
7. Quality risk: in the case of mass production, the batches of individual products may have quality problems, leading to the risk of return or even recall.
8. Contract / order risk: the execution of contracts and orders between the company’s U.S. subsidiaries and New York, Massachusetts and HHS (executed by ACC) in the United States is affected by local epidemic changes, policy changes, changes in the company’s supply chain capacity, logistics and transportation risks, unpredictable or force majeure and other factors, There may be a risk that the contract or order cannot be performed on schedule or in full.
In particular, the U.S. government has the right to terminate the contract at any time due to its own factors. The above meaning means that the U.S. government can request to stop the execution of the contract without any reason and cancel the subsequent procurement. The Seller shall bear the corresponding risks and possible losses.
In addition, the company also needs to remind investors of the following situations:
1. In the previous announcement, the company mentioned the epidemic prevention related plan issued by the U.S. government, as well as the relevant policies, procurement and distribution plans and conditions of covid-19 antigen household self-test kit products. Investors are reminded that the relevant information and procurement involved in the above contents are not only for the company. Investors are requested not to misunderstand the contents and mistakenly infer the changes it brings to the company’s performance.
2. Please refer to the announcement issued by the company for relevant information about the company’s performance.
3. At present, the company’s share price is at an all-time high, which does not rule out the risk of falling in the future. The company hereby reminds investors that the company will strictly implement the relevant provisions on information disclosure of listed companies and fulfill the obligation of information disclosure in time. It also takes this opportunity to remind investors again that there are many rumors on the Internet platform. Investors are requested to take the information officially released by the company as the standard and do not calculate the company’s performance and future trend without basis. There are many factors that affect the stock price of the secondary market, and the development of the epidemic in the United States in the future is still uncertain. The sales of kit products are affected by many factors. Investors should pay attention to investment risks and invest rationally.
Please correctly interpret the above contents, pay attention to risks and invest rationally.
It is hereby announced
Andon Health Co.Ltd(002432) board of directors
February 7, 2022
